Cargando…

APOE: The New Frontier in the Development of a Therapeutic Target towards Precision Medicine in Late-Onset Alzheimer’s

Alzheimer’s disease (AD) has a critical unmet medical need. The consensus around the amyloid cascade hypothesis has been guiding pre-clinical and clinical research to focus mainly on targeting beta-amyloid for treating AD. Nevertheless, the vast majority of the clinical trials have repeatedly failed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Anna, Kantor, Boris, Chiba-Falek, Ornit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7865856/ https://www.ncbi.nlm.nih.gov/pubmed/33513969 http://dx.doi.org/10.3390/ijms22031244

Ejemplares similares

Good problems to have? Policy and societal implications of a disease-modifying therapy for presymptomatic late-onset Alzheimer’s disease
por: Angrist, Misha, et al.
Publicado: (2020)

Probing the role of PPARγ in the regulation of late-onset Alzheimer’s disease-associated genes
por: Barrera, Julio, et al.
Publicado: (2018)

Sex-dependent effect of APOE on Alzheimer's disease and other age-related neurodegenerative disorders
por: Gamache, Julia, et al.
Publicado: (2020)

The Role of Upregulated APOE in Alzheimer’s Disease Etiology
por: Gottschalk, William K, et al.
Publicado: (2016)

Bioinformatics pipeline to guide late‐onset Alzheimer's disease (LOAD) post‐GWAS studies: Prioritizing transcription regulatory variants within LOAD‐associated regions
por: Lutz, Michael W., et al.
Publicado: (2022)

Gene-Editing Technologies Paired With Viral Vectors for Translational Research Into Neurodegenerative Diseases
por: Rittiner, Joseph Edward, et al.
Publicado: (2020)

Polygenic Risk Score Effectively Predicts Depression Onset in Alzheimer’s Disease Based on Major Depressive Disorder Risk Variants
por: Upadhya, Suraj, et al.
Publicado: (2022)

Shared genetic etiology underlying Alzheimer’s disease and major depressive disorder
por: Lutz, Michael W., et al.
Publicado: (2020)

Sex dependent glial-specific changes in the chromatin accessibility landscape in late-onset Alzheimer’s disease brains
por: Barrera, Julio, et al.
Publicado: (2021)

Cell-Type Specific Changes in DNA Methylation of SNCA Intron 1 in Synucleinopathy Brains
por: Gu, Jeffrey, et al.
Publicado: (2021)

Gene Expression Analysis of Neurons and Astrocytes Isolated by Laser Capture Microdissection from Frozen Human Brain Tissues
por: Tagliafierro, Lidia, et al.
Publicado: (2016)

Differential Gene Expression and DNA Methylation in the Risk of Depression in LOAD Patients
por: Upadhya, Suraj, et al.
Publicado: (2022)

Integrative single-nucleus multi-omics analysis prioritizes candidate cis and trans regulatory networks and their target genes in Alzheimer’s disease brains
por: Gamache, Julia, et al.
Publicado: (2023)

Neuropsychiatric Symptoms, Endophenotypes, and Syndromes in Late-Onset Alzheimer's Disease: Focus on APOE Gene
por: Panza, Francesco, et al.
Publicado: (2011)

Triad of Risk for Late Onset Alzheimer’s: Mitochondrial Haplotype, APOE Genotype and Chromosomal Sex
por: Wang, Yiwei, et al.
Publicado: (2016)

Immune targets for therapeutic development in depression: towards precision medicine
por: Drevets, Wayne C., et al.
Publicado: (2022)

Interpreting Gene Expression Effects of Disease-Associated Variants: A Lesson from SNCA rs356168
por: Glenn, Omolara-Chinue, et al.
Publicado: (2017)

Is ApoE ɛ 4 a good biomarker for amyloid pathology in late onset Alzheimer’s disease?
por: Ba, Maowen, et al.
Publicado: (2016)

Association between the APOE ε4 Allele and Late-Onset Alzheimer's Disease in an Ecuadorian Mestizo Population
por: Montufar, Stefany, et al.
Publicado: (2017)

RNA Biomarkers: Frontier of Precision Medicine for Cancer
por: Xi, Xiaochen, et al.
Publicado: (2017)

ApoE4: an emerging therapeutic target for Alzheimer’s disease
por: Safieh, Mirna, et al.
Publicado: (2019)

ApoE Lipidation as a Therapeutic Target in Alzheimer’s Disease
por: Lanfranco, Maria Fe, et al.
Publicado: (2020)

A TOMM40/APOE allele encoding APOE‐E3 predicts high likelihood of late‐onset Alzheimer’s disease in autopsy cases
por: Soyal, Selma M., et al.
Publicado: (2020)

Sex, ApoE4 and Alzheimer’s disease: rethinking drug discovery in the era of precision medicine
por: Paranjpe, Manish D., et al.
Publicado: (2021)

Precision Nutrition for Alzheimer’s Prevention in ApoE4 Carriers
por: Norwitz, Nicholas G., et al.
Publicado: (2021)

Molecular Insight into the Therapeutic Promise of Targeting APOE4 for Alzheimer's Disease
por: Mamun, Abdullah Al, et al.
Publicado: (2020)

Perspectives on the Role of APOE4 as a Therapeutic Target for Alzheimer’s Disease
por: Patel, Kavita, et al.
Publicado: (2021)

Neuronal ApoE4 in Alzheimer’s disease and potential therapeutic targets
por: Zhang, Lan, et al.
Publicado: (2023)

Effects of ApoE genotype on clinical phenotypes in early‐onset and late‐onset Alzheimer's disease in China: Data from the PUMCH dementia cohort
por: Dong, Liling, et al.
Publicado: (2021)

APOE and APOC1 gene polymorphisms are associated with cognitive impairment progression in Chinese patients with late-onset Alzheimer's disease
por: Zhou, Qin, et al.
Publicado: (2014)

Contributions of sex and genotype to exploratory behavior differences in an aged humanized APOE mouse model of late-onset Alzheimer's disease
por: McLean, John W., et al.
Publicado: (2022)

The Landscape of SNCA Transcripts Across Synucleinopathies: New Insights From Long Reads Sequencing Analysis
por: Tseng, Elizabeth, et al.
Publicado: (2019)

Apoe4 and Alzheimer’s Disease Pathogenesis—Mitochondrial Deregulation and Targeted Therapeutic Strategies
por: Pires, Mariana, et al.
Publicado: (2023)

Impact of gene variants on sex-specific regulation of human Scavenger receptor class B type 1 (SR-BI) expression in liver and association with lipid levels in a population-based study
por: Chiba-Falek, Ornit, et al.
Publicado: (2010)

Tau and TDP-43 synergy: a novel therapeutic target for sporadic late-onset Alzheimer’s disease
por: Latimer, Caitlin S., et al.
Publicado: (2021)

SHIP1 therapeutic target enablement: Identification and evaluation of inhibitors for the treatment of late‐onset Alzheimer's disease
por: Jesudason, Cynthia D., et al.
Publicado: (2023)

Effects of autologous serum on TREM2 and APOE in a personalized monocyte-derived macrophage assay of late-onset Alzheimer’s patients
por: Eren, Neriman, et al.
Publicado: (2023)

ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies
por: Raulin, Ana-Caroline, et al.
Publicado: (2022)

A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease
por: Hampel, Harald, et al.
Publicado: (2020)

Precision medicine’s new frontier: integrating palliative care at the right time
por: Sampetrean, A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0ta98qs21ib8caj2qpp09c3vs1